Health Science Policy Analyst
US Food & Drug Administration
Heather Stone, MPH is a Health Science Policy Analyst at the U.S. Food and Drug Administration in the Clinical Methodologies Group of the Office of Medical Policy, Center for Drug Evaluation and Research. Ms. Stone joined the FDA upon completing her Master’s in Public Health (Concentration: Epidemiology) from the University of Maryland School of Public Health in 2012. She attended Smith College as an undergraduate from 2006-2010, obtaining a Bachelor of Arts degree in Anthropology and a minor in Third World Development Studies.
Ms. Stone’s research focus is on the creation of policies that encourage drug development for infectious diseases and address the rising challenge of antimicrobial resistance. She applies her policy expertise to issues related to drug repurposing, clinical trial design, and antimicrobial drug development.
She is particularly interested in improving drug development for neglected, emerging, and resistant infectious diseases. Ms. Stone leads the development of a web and mobile platform for collecting case reports of repurposed treatments directly from clinicians globally, known as CURE ID. The project is a long-term collaboration between FDA, NIH/NCATS, and the Critical Path Institute. CURE ID, and it's associated public-private partnership - the CURE Drug Repurposing Collaboratory (CDRC) - is excited to be partnering with SCCM/Mayo's VIRUS registry, Johns Hopkins, UCSF, and Emory, along with many other partners, to be expanding the platform to enable automated data extraction of COVID-19 cases from EHRs and Registries.